Vimedimex Medi-Pharma JSC (HOSE:VMD)

Vimedimex Medi-Pharma JSC Balance Sheet

Financials in millions VND. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Cash & Equivalents	136,558	128,642	301,122	209,806	213,681	148,753
Short-Term Investments	260,265	224,900	33,960	39,649	42,695	31,158
Cash & Short-Term Investments	396,824	353,542	335,082	249,455	256,375	179,911
Cash Growth	8.06%	5.51%	34.33%	-2.70%	42.50%	-46.13%
Accounts Receivable	-	20,343	307,165	646,417	1,141,641	2,000,498
Other Receivables	12,548	62,651	199,624	406,871	163,986	163,544
Receivables	12,548	82,994	506,790	1,053,288	1,305,626	2,164,042
Inventory	7,655	19,475	84,864	247,076	947,132	2,531,669
Prepaid Expenses	9.41	-	1,706	1,617	4,175	2,896
Other Current Assets	218.27	-	47,861	62,826	299,011	401,119
Total Current Assets	417,255	456,011	976,303	1,614,262	2,812,320	5,279,637
Property, Plant & Equipment	43,123	44,500	110,781	134,506	132,700	146,847
Long-Term Investments	7,931	7,931	8,991	7,931	7,931	6,551
Other Intangible Assets	14,928	15,161	31,827	17,313	18,168	18,818
Long-Term Deferred Tax Assets	-	-	-	-	-	94.93
Other Long-Term Assets	872,229	1,648,644	69,552	76,284	82,402	79,558
Total Assets	1,355,465	2,172,247	1,197,455	1,850,296	3,053,522	5,531,506

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Accounts Payable	40.02	159,884	598,383	1,063,506	1,908,699	4,183,257
Accrued Expenses	-	-	20,147	9,797	17,043	221,264
Short-Term Debt	-	-	-	-	-	612,374
Current Income Taxes Payable	8,325	8,934	5,931	3,489	5,880	-
Current Unearned Revenue	-	-	-	224.02	151.5	-
Other Current Liabilities	6,957	108,270	137,870	332,149	682,301	94,179
Total Current Liabilities	15,321	277,089	762,331	1,409,165	2,614,073	5,111,074
Other Long-Term Liabilities	767,004	1,362,127	18,470	20,077	20,746	23,664
Total Liabilities	782,325	1,639,216	780,800	1,429,242	2,634,819	5,134,738

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Common Stock	154,403	154,403	154,403	154,403	154,403	154,403
Additional Paid-In Capital	114,168	114,168	114,168	114,168	114,168	114,168
Retained Earnings	128,866	98,596	59,418	64,348	71,623	53,266
Comprehensive Income & Other	7,338	7,338	9,262	9,262	9,262	8,206
Total Common Equity	404,776	374,506	337,251	342,181	349,456	330,042
Minority Interest	168,364	158,525	79,404	78,873	69,246	66,726
Shareholders' Equity	573,140	533,031	416,654	421,054	418,702	396,768
Total Liabilities & Equity	1,355,465	2,172,247	1,197,455	1,850,296	3,053,522	5,531,506

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Jan 1, 2025	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Total Debt	-	-	-	-	-	612,374
Net Cash (Debt)	396,824	353,542	335,082	249,455	256,375	-432,463
Net Cash Growth	8.06%	5.51%	34.33%	-2.70%	-	-
Net Cash Per Share	25700.56	22897.43	21701.83	16152.32	16604.34	-28008.76
Filing Date Shares Outstanding	15.44	15.44	15.44	15.44	15.44	15.44
Total Common Shares Outstanding	15.44	15.44	15.44	15.44	15.44	15.44
Working Capital	401,933	178,922	213,972	205,097	198,247	168,563
Book Value Per Share	26215.59	24255.14	21842.28	22161.60	22633.91	21375.44
Tangible Book Value	389,848	359,345	305,423	324,868	331,288	311,224
Tangible Book Value Per Share	25248.75	23273.25	19780.96	21040.32	21457.18	20156.64
Buildings	23,376	23,376	78,941	77,896	77,896	79,708
Machinery	25,843	25,843	120,033	120,033	108,504	108,463
Construction In Progress	32,242	32,242	33,905	46,972	41,385	40,563

Data Source: S&P Global Market Intelligence Last updated: Sep 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 20, 2026

Data Sources Report a data error